Effect of RANKL Inhibition on UV-induced Immunosuppression

NCT01978483 · clinicaltrials.gov ↗

PHASE1

Phase

COMPLETED

Status

31

Enrollment

OTHER

Sponsor class

Conditions

Ultraviolet Rays
Immunosuppression
Hypersensitivity, Delayed
Immune Tolerance/Drug Effects

Interventions

DRUG: Denosumab
RADIATION: UVB exposure
DRUG: Diphenylcyclopropenone
DRUG: Normal Saline

Sponsor

Innovaderm Research Inc.